
price close busi march
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
diagnost tool
posit surpris draft lcd continu
treat kidney free call option buy pt
surpris issu draft local coverag decis palmetto moldx
prospera newli name brand blood-bas kidney transplant reject
test compani expect launch end model
continu model zero revenu assay howev draft lcd mind
increas probabl launch test medicar reimburs
believ prior yesterday investor analyst expect kept low
render show-m launch even trade yesterday news
trade revenue estim opinion
materi disconnect current valuat busi actual
worth rais pt get posit news acog
acog annual meet may think stock could hit all-tim high gap
rais price target top list top pick
time kidney draft lcd ahead expect draft lcd
palmetto came least quarter ahead low expect draft lcd
check number box thu far complet analyt clinic
valid earn draft local coverag decis lcd palmetto moldx complet
clia valid obtain z-code view make eoy launch
look feasibl confid achiev final medicar
decis end vs prior hope either late earli
expect much traction kidney test even
model zero given lack visibl final medicar reimburs time
launch among variabl
step comment draft lcd begin roll may end june
view could result final reimburs decis end
frankli posit time expect
ntra kidney test prospera ntra prospera assay cell-fre dna-bas
assay target single-nucleotid polymorph quantifi
fraction dd-cfdna transplant recipi blood even relat recipient/donor
pair without separ genotyp either donor recipi
differenti allosur organ transplant reject test market
leader allosur assay target assay use single-nucleotid
polymorph vs ntra quantifi dd-cfdna transplant
recipi without separ genotyp donor recipi believ prospera
differenti allosur test high sensit t-cell mediat
antibodi mediat reject abil detect subclin reject occur
patient first two year post-transpl
build evid post-market studi underway submit
peer-review public dd-cfdna clinic util random control trial
studi physician-report current clinic practic impact prospera dd-
cfdna registri studi assess prospera impact actual biopsi usag
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
criteria coverag prospera assay cover follow condit
met recipi first-tim renal allograft patient physician-
assess pretest evalu patient probabl activ renal
allograft reject medicar coverag avail kidney transplant patient
regardless age either primari secondari insur minimum month
follow success transplant compar allosur test
cover renal allograft recipi age
physician-assess pretest need assess patient probabl activ
renal allograft reject test perform least two week post-transpl
deliv revenu beat earlier month revenu
y/i beat manag indic us
improv collect prior period recogn revenu
appeal revenu older claim level like may repeat
drove volum growth gm basic flat
exceed estim opex basic line
think net loss beat net loss estim
million bgi deal announc deal bgi genom
march call indic expect net cash up-front
bgi deal manag treat cash payment
plan recogn futur work revenu agreement
bgi pay million up-front licens fee prepaid royalti
also receiv on-going royalti payment manag indic call
expect sum ten million dollar time think
unreason given million peopl china live cancer
number american live cancer accord
prepay bgi genom sequenc servic reagent relat
partnership ntra signatera mrd minim residu diseas molecular
monitor test offer china first specialti hospit network without
need cfda approv broadli follow like cfda regulatori approv
signatera mrd bgi dnbseq instrument platform indic call
cfda approv burdensom process suggest bgi may
commerci signatera test china
bgi deal strengthen balanc sheet payment bgi de-risk natera
balanc sheet materi posit view held cash end
thu expect net proce like come
month size pro-forma cash balanc million guid
cash burn thu think runway growth certainli
guid opex y/i midpoint
level growth exceed revenu guidanc call growth
believ highli like revenu growth acceler compar
bgi enabl offer huge import china market bgi provid
highli respect partner larg china market further global
expans goal use import supplier chang
exist suppli agreement held posit sequenc
agnost decentr test enabl peopl world run test sampl
local site sequenc vs send sampl ntra lab ca
done partnership bgi think remind investor
deal announc time last year strictli relat pre-
natal test thu think done announc addit strateg deal
believ would logic want access compel oncolog
test menu even see partnership outsid bgi recal
work thermo fisher subsidiari alreadi one lambda transplant
market thu rule possibl sign deal thermo use
ion torrent sequenc perhap access part world mayb
may commerci strength
acog expect steadi improv average-risk nipt reimburs
provid timet acog decis spoke
buy unchang target price march
diagnost tool
manag topic call sens support build
nice consortium nipt compani tri build support new acog
bulletin note acog annual meet may nashvil
view aggreg feedback outreach import player like
lh other may lead critic decis five week
indic call new guidanc way support
averag risk nipt still wait acog publish new bulletin
engag aet think coverag polici decis inevit
get paid time average-risk nipt volum think
reason could get paid roughli time least end
view expect payor outsid aet come well
step-funct increas pharma revenu build confid target
contract valu pharma increas vs
cumul contract valu driven pharma interest
signatera ruo test minim residu diseas mrd molecular monitor
natera indic contract valu convert revenu cours
month thu expect modest contribut oncolog
revenu pick beyond end indic
studi trial pharma includ pharma
lead io compani studi trial
cancer indic lung breast colon prostat pan-canc applic one
notabl exampl bm use help determin patient receiv
chemo alon chemo opdivo expect mani deal come meaning
entri kidney transplant diagnost complet analyt
valid clinic valid held pre-submiss meet obtain draft local
coverag decis lcd complet clia valid obtain z-code
hope launch kidney test end expect comment period
follow final lcd end think earliest achiev
final medicar decis end earli dont expect meaning
revenu kidney even model zero given
lack visibl product launch reimburs
kidney investor ask us stand market
leader transplant dx answer ye cours model zero rev
kidney test thu expect alreadi zero transplant believ
postur conservat particularli beyond
buy unchang target price march
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price march
diagnost tool
buy unchang target price march
diagnost tool
buy unchang target price march
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin march et
date time product march et
pt use multipl revenu estim y/i discount back two year discount rate
dilut share outstand
price target use multipl adj ep estim assum view modest
earn growth project believ potenti faster top-lin growth accret capit
deploy would mark upsid ep estim
pt use multipl adj ep estim
laboratori corpor america hold lh
price target lh appli multipl adj ep
risk achiev target price valuat
panorama asp compress erod margin gross margin drop sequenti expect
margin continu erod result reduct in-network price commerci payor come on-line
expand includ averag risk patient expect mitig revenu impact asp compress drive
busi profit account though busi may suffer increas test volum outpac asp
relianc lab partner move away lab partner priorit direct sale continu sell
number refer lab partner includ arup clarient sonic unclear durabl compani lab partnership may
particularli sinc lost lab partner past certain lab choos promot anoth nipt decid offer
nipt includ recent quest
fda oversight ldt test lab-develop test ivd fda take posit author
regul test medic devic fdc act gener chosen enforc author mandat certain
ltd seek fda clearanc howev fda look regul ldt use risk-bas approach begin deem
highest-risk devic follow lower risk devic believ panorama would treat moderate-risk high-risk
among highest-risk devic fda indic high-and moderate-risk ltd market
guidelin final remain market fda review submiss expect requir
remov product market regul fda ltd remain subject uncertainti controversi
constel addit talk fda receiv clearanc constel us fda indic
constel platform may appropri review de novo classif allow market
distribut constel us convers on-going fda requir obtain regulatori clearanc
market constel softwar diagnost purpos abl secur fda clearanc compli
on-going fda regulatori requir would unabl commerci constel compani cloud-bas distribut
buy unchang target price march
diagnost tool
competit compet directli compani offer nipt carrier screen test ob/gyn mfm
market labcorp roch counsyl mani compani larger abl
leverag economi scale win busi offer multipl test servic women health one requisit form
observ research doctor often switch test brand may make market share gain difficult
strong competit oncolog uncertain time oncolog launch develop liquid biopsi test oncolog
manag size opportun billion initi sampl collect activ lung ovarian
cancer collect dozen collabor includ vanderbilt stanford columbia cancer research uk
other also initi collect effort breast cancer plan announc collabor later year
alon pursu blood-bas test oncolog market leader today substanti base revenu data
counsyl trovagen pathway genom mdx name hand
ethic legal social concern relat genet inform could reduc demand genet test test provid
dna test servic like conduct use panorama expect conduct oncolog may rais ethic legal
social issu regard privaci appropri use result inform government author could social
purpos limit regul use genom inform genom test prohibit test genet predisposit certain
condit particularli known cure similarli concern may lead patient refus use genet test even
permiss ethic social concern may also complic abil protect patent technolog
import medicaid nipt approxim birth unit state state medicaid program recipi
end recogn medicaid provid state state requir compani oper lab
state becom recogn medicaid provid typic medicaid rate price medicar commonli lowest payor
term dollar
econom downtown would impact busi unemploy rate hover around variou macroeconom
headwind potenti reduc demand diagnost servic especi drugs-of-abus doa pre-employ test
rel cyclic busi segment revenu volum
healthcar reform lead medicar reimburs cut quest deriv approxim net revenu medicar
medicaid program combin medicar clinic lab fee schedul clf medicar physician fee schedul
medicaid lab industri provid face declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost
quest face competit threat could slow growth quest compet primarili labcorp along numer smaller
independ nich clinic laboratori also compet hospit lab quest slightli larger scale scope
labcorp smaller competitor may prove nimbl innov quest labcorp australian-bas sonic healthcar
build signific presenc compet quest acquisit northeast compet bio-refer
lab compani deriv revenu higher-margin esoter test
negoti health plan plan includ manag care organ health insur provid repres
approxim compani volum revenu compani largest health plan aetna repres approxim
compani revenu quest compet aggress labcorp contract health plan larg price margin
contract length quest largest health plan account approxim revenu volum
believ key risk includ major new product launch novaseq instrument premium valuat excess
peer group risk associ demand pace novaseq placement hiseq unit decommiss
competit noise/tract though believ meaning competit risk well bay nih/govern budgets/
spend particularli foreign govern like japan genom research center regulatori risk fda addit
risk factor less concern includ typic medic technolog risk price instrument consum risk
associ move test clinic increas compani focu bioinformat long-term also
highlight spend scale helix
laboratori corpor america hold lh
labcorp integr covanc macroeconom weak may threaten volum margin unemploy rate
hover around variou macroeconom headwind potenti reduc demand diagnost servic especi drugs-
of-abus doa pre-employ test rel cyclic busi segment roughli volum revenu
healthcar reform may lead medicar reimburs cut labcorp deriv revenu medicar medicaid
program lab industri provid face risk declin reimburs medicar feder govern seek
curb acceler growth rate healthcar cost believ all-in medicar reimburs rate lab increas
modestli expect medicar reimburs declin approxim labcorp face competit threat
could slow growth labcorp compet industri leader quest diagnost along numer smaller independ nich
clinic laboratori quest slightli larger scale scope labcorp smaller competitor may prove nimbl
innov labcorp australian-bas sonic healthcar build signific presenc
buy unchang target price march
diagnost tool
compet labcorp acquisit northeast lh compet bio-refer lab compani deriv
revenu higher-margin esoter test negoti health plan plan includ manag care organ
health insur provid repres approxim compani volum revenu compani largest health
plan exclus contract end repres approxim revenu estim
labcorp compet aggress quest contract health plan larg price margin contract length
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
